Fast Market Research

Bladder Cancer - Pipeline Review, H1 2014 - New Market Report

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research


Boston, MA -- (SBWIRE) -- 04/11/2014 -- Global Markets Direct's, 'Bladder Cancer - Pipeline Review, H1 2014', provides an overview of the Bladder Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

View Full Report Details and Table of Contents

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Companies Mentioned in this Report: Shionogi & Co., Ltd., AstraZeneca PLC, Eli Lilly and Company, Viralytics Ltd., GlaxoSmithKline plc, Bioniche Life Sciences, Inc., Biotest AG, Samyang Holdings Corporation, Astellas Pharma Inc., Eisai Co., Ltd., Marina Biotech, Inc., Taiho Pharmaceutical Co., Ltd., Celgene Corporation, Advaxis, Inc., Evotec AG, Immunomedics, Inc., Alnylam Pharmaceuticals, Inc., Oncogenex Pharmaceuticals, Inc., Dendreon Corporation, Sanochemia Pharmazeutika AG, Quest PharmaTech Inc., Med Discovery SA, Hutchison MediPharma Limited, Altor BioScience Corporation, Telormedix SA, Gene Signal International SA, MacroGenics, Inc., Innate Therapeutics Limited, Stemline Therapeutics, Inc., BioCancell Therapeutics, Inc., AndroScience Corporation, Pharma Mar, S.A., NuCana BioMed Limited, Polaris Group, Serometrix, LLC, Regulon Inc., SentoClone International AB, Optimum Therapeutics, LLC, Lipella Pharmaceuticals, Inc., APIM Therapeutics AS, Qu Biologics Inc., Panacela Labs, Inc., Oncopeptides AB, DormaTarg, Inc., AlphaMab Co., Ltd

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Colon Cancer - Pipeline Review, H1 2014
- Small-Cell Lung Cancer - Pipeline Review, H1 2014
- Cervical Cancer - Pipeline Review, H1 2014
- Metastatic Colorectal Cancer - Pipeline Review, H1 2014
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014
- Fallopian Tube Cancer - Pipeline Review, H1 2014
- Peritoneal Cancer - Pipeline Review, H1 2014
- Metastatic Pancreatic Cancer - Pipeline Review, H1 2014
- Endometrial Cancer - Pipeline Review, H1 2014
- Epithelial Ovarian Cancer - Pipeline Review, H1 2014